On Monday, April 15, the Supreme Court heard oral argument in a patents case, Association for Molecular Pathology v. Myriad Genetics, Inc, concerning whether human genes can be patented. Myriad Genetics, which identified two sections of the genetic code that might indicate higher risk for certain types of cancer, obtained patents on the "isolated" or removed versions of these two genes on the basis that Myriad invented a new chemical in the process of identifying and removing these genes from the body. The challengers claim that Myriad Genetics has created nothing new, but rather the process is an examination of a substance found in nature whose attributes remain unchanged. What will the Court’s decision hold for a field where thousands of gene patents have already been secured? Do such patents inhibit or promote further such discoveries, or is the evidence clear? Our expert, who attended the oral argument, will discuss and provide his thoughts on the case and answer questions from callers.
- Prof. Gregory Dolin, Associate Professor and Co-Director, Center for Medicine and Law, University of Baltimore School of Law
Teleforum calls are open to all dues paying members of the Federalist Society. To become a member, sign up here. As a member, you should receive email announcements of upcoming Teleforum calls which contain the conference call phone number. If you are not receiving those email announcements, please contact us at 202-822-8138.
Call begins at 2:00 p.m. Eastern Time.